Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Stock Jumps After FDA Announcement on Smokeless Tobacco Products

  • LXRP stock jumped by 24 percent following the FDA’s announcement
  • FDA recently granted the first-ever, modified-risk orders to eight smokeless tobacco products
  • DehydraTECH technology enhances oral delivery of nicotine

The recent climb in the stock price of Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) looks to be the harbinger of a bright future for the innovative global developer of drug-delivery platforms. After the FDA announced it had authorized the marketing of products through the modified-risk, tobacco-product (MRTP) pathway, LXRP stock jumped 24 percent, up to $0.72 from $0.58 on the OTC Markets. The rapid rise in Lexaria stock price is a sure indication that investors are betting some of those product categories approved by the FDA could benefit from Lexaria’s drug-delivery platform. The company’s patented DehydraTECH(TM) technology has been shown to enhance the oral delivery of nicotine and a wide range of other active pharmaceutical agents.

The FDA announcement is a victory of vindication for companies such as Lexaria that are developing smokeless nicotine products and technology. While smokeless tobacco products are widely sold, in the past they cannot profess to be healthier than cigarettes to use. However, following the FDA announcement, some can. On October 22, 2019, the FDA allowed ( eight smokeless-tobacco products to make the claim that their use “instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.”

The FDA approval of the “modified risk” claims was made after reviewing scientific evidence submitted by the manufacturer of the products. The approvals, which are product specific and expire after five years, do not mean the products come with no health risks. Nicotine-based products are addictive and may, according to some studies, induce the onset of cardiovascular, respiratory and gastrointestinal disorders.

The patented DehydraTECH drug-delivery platform mitigates a serious limitation to nicotine ingestion. The human GI system struggles to process nicotine in the forms in which it is presently offered, one reason why there are currently no edible, nicotine, manufactured products available, although some natural foods – eggplant, green pepper, potato, tomato – do contain nicotine. However, DehydraTECH employs a delivery mechanism that improves the bioabsorption and bioavailability of many ingestible substances, as well as their taste and smell, by using lipophilic agents. Application of the technology extends beyond nicotine to non-psychoactive cannabinoids, vitamins and non-steroidal anti-inflammatory drugs (NSAIDs).

Lexaria has licensed the DehydraTECH technology to a number of companies, including one of the world’s largest tobacco corporations, in a collaboration to pursue the development of reduced-risk, oral-nicotine consumer products. Lexaria recently provided an update on that partnership. “Most of the investigation and work within this first phase of the project is either complete or significantly underway, with one remaining aspect ready to commence imminently,” the company reported ( “To date, results have been positive and are supportive of successfully completing this first phase. Successful completion of phase one will be the first step in developing commercially viable products using Lexaria’s technology.”

As of July 2019, Lexaria had nine corporate licensees, with whom it had signed 11 licensing agreements to develop products using its DehydraTECH absorption technology ( These are potentially lucrative six-figure contracts that typically yield 90 percent plus of revenues as profit. Tobacco continues to be an area of opportunity. Presently, the tobacco industry generates about 20 times more revenue than the cannabis industry

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit

MissionIR (MIR)
Atlanta, Georgia
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published:

This entry was posted in Lexaria Bioscience Corp. (LXRP). Bookmark the permalink.

Comments are closed.